Bibliografía del artículo
1. Chopra I, Hawkey, PM, Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother 1992; 29(3):245-77.
2. Website. http://www.fda.gov/cder/rdmt/InternetPriority05.htm [Accessed 5-30-2006].
3. Petersen PJ, Jacobus NV, Weis WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylglycine, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43(4):738-44.
4. Schnappinger D, Hillen W. Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch Microbiol 1996; 165(6):359-69.
5. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65(2):232-60.
6. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacother 2000; 20(9Pt2):219S-23S.
7. Sum PE, Sum FW, Projan SW. Recent developments in tetracycline antibiotics. Curr Pharm Des 1998; 4(2):119-32.
8. Rasmussen BA, Gluzman Y, Tally FP. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents Chemother 1994; 38(7):1658-60.
9. Bauer G, Berens C, Projan SJ Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53(4):592-9.
10. Fluit AC, Florijn A, Verhoef J. Milatovic D. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 2005; 49(4):1636-8.
11. Someya Y, Yamaguchi A, Sawai T. A novel glycylcycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline/H+ antiporter. Antimicrob Agents Chemother 1995; 39(1):247-9.
12. Hirata T, Saito A, Nishino K, Tamura N, Yamaguchi A. Effects of efflux transporter genes on suscpetibility of
Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother 2004; 48(6):2179-84.
13. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigecycline (GAR-936) in
Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47(3):972-8.
14. Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in
Morganella morganii. Antimicorb Agents Chemother 2005; 49(2):791-3.
15. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program 2004). Diagn Microbiol Infect Dis 2005; 52(3):215-27.
16. Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones, RN. Activity of tigecycline tested against a global collection of
Enterobacteriaceae, including tetracycline-resistant isolates. Diagn Microbiol Infect Dis 2005; 52(3):209-13.
17. Sader HS, Jones RN, Stilwell, MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005; 52(3):181-6.
18. Jones CH, Tuckman M, Howe AYM, et al. Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among
Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections. Antimicrob Agents Chemother 2006; 50(2):505-10.
19. Visalli MA, Murphy E, Projan SJ, Bradford, PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in
Proteus mirabilis. Antimicrob Agents Chemother 2003; 47(2):665-9.
20. Ruzin A, Visalli MA, Keeney D, Bradford PA. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in
Klebsiella pneumoniae. Antimicrob Agents Chemother 2005; 49(3):1017-22.
21. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylclycine, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43(4):738-44.
22. Garvis S, Mei JM, Ruiz-Albert J, Holden DW.
Staphylococcus aureus svrA: a gene required for virulence and expression of the agr locus. Microbiol 2002; 148(10):3235-43.
23. Schmitz F-J, Fluit AC. Mechanisms of resistance. In: Infectious Diseases. Armstrong D, Cohen S eds. Mosby 1999, p. 7.2.1-14.
24. Morita Y, Kodama K, Shiota S, et al. NorM, a putative multidrug efflux protein, of
Vibrio parahaemolyticus and its homolog in
Escherichia coli. Antimicrob Agents Chemother 1998; 42(7):1778-82.
25. McAleese F, Petersen P, Ruzin A, et al. A Novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived
Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 2005; 49(5):1865-71.
26. Moore IF, Hughes DW, Wright GD. Tigecycline is modified by the flavin-dependent mooxygenase TetX. Biochem 2005; 44(35):11829-35.